Exact Sciences Corp., which provides cancer screening and diagnostic tests, on Tuesday announced the launch of Oncodetect — a new test designed to detect molecular residual disease (MRD) across multiple solid tumors. The Oncodetect test provides patients and their health care providers with the insights needed to make more informed decisions throughout the treatment process.
The Oncodetect test delivers clear “detected” or “not detected” results, along with quantitative data to help support adjuvant therapy decisions, evaluate treatment response and monitor cancer recurrence.
Exact Sciences is working with Medicare to secure reimbursement for the test, ensuring broad patient access nationwide. The company is also advancing clinical and analytical validation studies across multiple solid tumors, supported by strategic partnerships for multi-cancer evidence generation.
The Oncodetect test is now available. For more information, click here.
